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Assessing the healthcare resource use
associated with inappropriate prescribing
of inhaled corticosteroids for people with
chronic obstructive pulmonary disease
(COPD) in GOLD groups A or B: an
observational study using the Clinical
Practice Research Datalink (CPRD)
James D. Chalmers1, Chris Poole2, Samantha Webster2*, Abigail Tebboth2, Scott Dickinson2 and Alicia Gayle2
Abstract
Background: Recent recommendations from the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
position inhaled corticosteroids (ICS) for use in chronic obstructive pulmonary disease (COPD) patients experiencing
exacerbations (≥ 2 or ≥ 1 requiring hospitalisation); i.e. GOLD groups C and D. However, it is known that ICS is
frequently prescribed for patients with less severe COPD. Potential drivers of inappropriate ICS use may be historical
clinical guidance or a belief among physicians that intervening early with ICS would improve outcomes and reduce
resource use. The objective of this study was to compare healthcare resource use in the UK for COPD patients in
GOLD groups A and B (0 or 1 exacerbation not resulting in hospitalisation) who have either been prescribed an
ICS-containing regimen or a non-ICS-containing regimen.
Methods: Linked data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)
database were used. For the study period (1 July 2005 to 30 June 2015) a total 4009 patients met the inclusion
criteria; 1745 receiving ICS-containing therapy and 2264 receiving non-ICS therapy. Treatment groups were
propensity score-matched to account for potential confounders in the decision to prescribe ICS, leaving 1739
patients in both treatment arms. Resource use was assessed in terms of frequency of healthcare practitioner (HCP)
interactions and rescue therapy prescribing. Treatment acquisition costs were not assessed.
Results: Results showed no benefit associated with the addition of ICS, with numerically higher all-cause HCP
interactions (72,802 versus 69,136; adjusted relative rate: 1.07 [p = 0.061]) and rescue therapy prescriptions (24,063
versus 21,163; adjusted relative rate: 1.05 [p = 0.212]) for the ICS-containing group compared to the non-ICS group.
Rate ratios favoured the non-ICS group for eight of nine outcomes assessed. Outcomes were similar for subgroup
analyses surrounding potential influential parameters, including patients with poorer lung function (FEV1 < 50%
predicted), one prior exacerbation or elevated blood eosinophils.
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Conclusions: These data suggest that ICS use in GOLD A and B COPD patients is not associated with a benefit in
terms of healthcare resource use compared to non-ICS bronchodilator-based therapy; using ICS according to GOLD
recommendations may offer an opportunity for improving patient care and reducing resource use.
Keywords: Chronic obstructive pulmonary disease, Resource use, Inhaled corticosteroids, Long-acting
bronchodilators
Background
Chronic obstructive pulmonary disease (COPD) remains
a significant contributor to healthcare resource use due
to its considerable morbidity and mortality. According
to data at 2012, an estimated 1.2 million people in the
UK had diagnosed COPD, and it is now the third leading
cause of death globally [1, 2].
Inhaled bronchodilators, such as long-acting β2 ago-
nists (LABAs) and long-acting muscarinic antagonists
(LAMAs), are commonly used for symptom manage-
ment in patients with COPD [3]. These can be pre-
scribed as monotherapies, in fixed dose combinations or
in combination with inhaled corticosteroids (ICS).
LABA+LAMA combinations have been shown to im-
prove lung function and breathlessness, and reduce ex-
acerbations compared to ICS + LABA treatment [4–7].
Further, studies have shown that overuse of ICS therap-
ies is associated with increased risk of complications
such as oral candidiasis, hoarse voice, skin bruising,
pneumonia and fractures [2, 8–13]. As a result, the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) 2017 strategy recommends combination bron-
chodilator therapy for patients with stable COPD to pre-
vent or reduce symptoms, and that ICS-containing
therapies should be reserved for patients categorised as
group C or D; i.e. exacerbating patients (≥ 2 or ≥ 1 re-
quiring hospitalisation) [2].
ICS is indicated for the treatment of patients with
moderate-to-severe COPD and a history of exacerba-
tions. Despite this, several studies have found that
this does not reflect current clinical practice, and ICS
is commonly prescribed in patients with less severe
COPD [3, 14–17].
Some clinicians have advocated prescribing of ICS to
patients with less severe disease in specific subgroups,
e.g. those with asthma–COPD overlap features or ele-
vated peripheral blood eosinophil count, with the goal
of preventing exacerbations and thereby reducing
healthcare resource use. This may be partially attrib-
uted to guidance issued by the National Institute of
Health and Care Excellence (NICE) in 2010, which rec-
ommended ICS + LABA therapy for patients with
forced expiratory volume in 1 s (FEV1) < 50% predicted
and remain breathless or have exacerbations despite
maintenance LABA therapy [18]. There is little
published evidence on the healthcare resource implica-
tions resulting from earlier initiation of ICS. Large
randomised controlled trials of ICS use have mainly
enrolled patients with severe COPD and frequent exac-
erbations, and have limited follow-up. Real world data
can supplement those from randomised controlled tri-
als by providing more detailed healthcare utilisation
and longer-term follow-up.
This study therefore aimed to supplement the existing
evidence by investigating the prescribing patterns in the
UK for a large cohort of COPD patients in GOLD
groups A and B (0 or 1 exacerbation not requiring
hospitalisation) [17], and evaluate the impact of ICS use
in in terms of healthcare resource utilisation.
Methods
Study design, participants, and setting
This was a descriptive, population-based longitudinal
study using routinely collected healthcare data provided
by the Clinical Practice Research Datalink (CPRD).
CPRD contains electronic primary care records from
general practice in the UK, and is one of the largest da-
tabases of longitudinal medical records from primary
care in the world [19]. The quality of data in CPRD is
subject to rigorous checks and regular audits, and has
been used to conduct a large number of published phar-
macoepidemiologic studies [20–22]. Linkage between
CPRD and Hospital Episode Statistics (HES) data is also
available, enabling individual anonymised patient records
to be followed across care sectors.
For inclusion in the study, patients were required to
be of acceptable patient standard (as defined by
CPRD), registered with “up-to-standard” practices for
the period of observation, and eligible for linkage
with HES. The study population included patients
aged ≥40 years with a new diagnosis of COPD (based
on any record of a diagnostic read code for COPD in
addition to spirometry confirmation of the diagnosis
[FEV1/forced vital capacity {FVC} ratio < 0.7]) during
the study period (1 July 2005 to 30 June 2015) and
classified as GOLD category A/B (captured according
to exacerbation history). Exacerbations were defined
using a validated CPRD algorithm (antibiotic and oral
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corticosteroid prescriptions for 5–14 days calculated using
date of prescription and drug pack information, or lower
respiratory tract infection read code or acute exacerbation
read code) [23]. The accuracy of COPD diagnosis in
CPRD has been validated [24]. Patients were also required
to have a prescription of maintenance bronchodilators
within three months of diagnosis, and at least one full year
of data prior to the index date (date of the last prescrip-
tion within three months of diagnosis date). Patients with
a diagnostic read code for asthma within one year or those
with a record of treatment with a LAMA, LABA, ICS or
any combination of these in the year prior to the index
date, were excluded. The read codes applied are available
in the Additional file 1.
Fig. 1 Patient selection flow chart. COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; GOLD, Global Initiative
for Chronic Obstructive Lung Disease; HES, Hospital Episode Statistics; ICS, inhaled corticosteroid
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Outcomes of interest
In order to quantify healthcare resource use in the popu-
lation under consideration, the following all-cause out-
comes were accumulated: number of interactions with a
healthcare practitioner (HCP); number of hospital ad-
missions; and number of short-acting bronchodilator
prescriptions (i.e. rescue therapy). These endpoints were
also assessed according to respiratory-related (as op-
posed to all-cause) read codes; however, this was consid-
ered a supplementary exploratory assessment due to the
requirement to considerably restrict read codes to those
exclusively associated with COPD (i.e., read codes for
breathlessness and chest pain were excluded since these
could not be exclusively be attributed to COPD; see
Additional file 1). Treatment costs were not considered.
Analysis
After identification of records meeting inclusion cri-
teria, patients were stratified according to their pre-
scription at index date and followed until the first of:
discontinuation of treatment; last record of treatment
plus 28 days (to allow for treatment period); date of
initiation of an alternative treatment (i.e. switch from
ICS- to non-ICS-containing treatment or vice versa)
less one day; patient’s transfer out of practice; practice
last collection date; end of study period; or death.
The ICS group contained patients prescribed ICS as
part of maintenance therapy in any combination or
alone; the non-ICS group contained patients pre-
scribed any regimen not including ICS.
Patients in the ICS and non-ICS groups were propensity
score matched to account for potential biases, as well as to
adjust for the difference in individual comorbidities (body
mass index [BMI] kg/m2, modified Medical Research
Council [mMRC] score, FEV1 [% predicted], diagnosis of
type 2 diabetes, diagnosis of osteoporosis, previous stroke,
previous pneumonia, prior exacerbations, Index of Multiple
Deprivation [IMD]). Propensity scores were created using a
published logistic regression model [17]. Groups were pair
matched by propensity score at a ratio of 1:1 using a greedy
nearest-neighbour matching algorithm. Pairs were matched
on the logit of the propensity score, and calipers of width
equal to one standard deviation of the logit of the propen-
sity score were used.
A comparison of baseline characteristics across the
two treatment groups was performed using Χ2 or T-tests
and paired T-tests and McNemar tests for matched
comparisons, as appropriate. Prevalence was calculated
for binary or categorical characteristics, and mean and
standard deviation for continuous characteristics. Miss-
ing data were quantified for each variable. For the major-
ity of variables, data were considered to be missing at
random (unlikely to bias the estimated results) and
classified as unknown.
Outcomes of interest were compared for the ICS and
non-ICS groups, with subgroup analyses assessing the
impact of potentially relevant confounders; this included
group A/B patients with FEV1 < 50% predicted, one
prior exacerbation (i.e. removal of patients that had
not experienced an exacerbation) and an eosinophil
count > 0.3 × 109/L (selected based on recent literature
that suggested a benefit of ICS in patients with an
eosinophil count above this level) [17, 25, 26]. Rate ratios
were estimated using zero-inflated negative binomial
regression of the number of events, in order to take into
account individuals more prone to repeated events and
provide more conservative confidence intervals and
p values. We compared a univariate analysis with the
fully adjusted model.
Results
A total of 4009 patients with newly diagnosed GOLD
A/B COPD and a prescription for maintenance bron-
chodilation treatment within three months of diagno-
sis were identified (see Fig. 1).
The treatments prescribed to patients within three
months of COPD diagnosis are displayed in Fig. 2; 44%
of the cohort was prescribed an ICS-containing regimen.
There was no statistically significant difference be-
tween most groups prior to propensity score matching;
following matching, any differences between groups
were controlled for. After matching, 531 patients were
excluded, leaving a total matched-cohort size of 3478.
On average, patients had 31 months of follow-up
(standard deviation [SD] 24 months). Total patient years
of follow up were 4348 in the ICS group versus 4686 in
the non-ICS group. As the mean difference in follow-up
time was minimal, no adjustment was made in the
subsequent analysis.
Fig. 2 Treatments prescribed within three months of COPD
diagnosis. COPD, chronic obstructive pulmonary disease; ICS,
inhaled corticosteroid; LABA, long-acting β2 agonist; LAMA,
long-acting muscarinic antagonist; SABA, short-acting β2 agonist;
SAMA, short-acting muscarinic antagonist
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Table 1 Patient baseline demographics and characteristics pre- and post-matching
Parameter Pre-matching Post matching
ICS (N = 1745) Non-ICS (N = 2264) P value ICS (N = 1739) Non-ICS (N = 1739) P value
Female, n (%) 679 (38.9) 906 (40.0) 0.494 676 (38.9) 697 (40.1) 0.480
Mean age, years (SD) 67.6 (10.3) 68.0 (10.3) 0.237 67.6 (10.3) 67.9 (10.2) 0.480
Mean BMI, kg/m2 (SD) 27 (5.8) 27 (5.8) 0.4189 27 (5.8) 27 (6.0) 0.3166
Mean FEV1 predicted, % (SD) 57 (19.4) 61 (18.5) < 0.001 57 (19.4) 61 (18.5) < 0.001
Age category, n (%)
40–44 years 29 (1.7) 26 (1.1) 0.321 27 (1.6) 21 (1.2) 0.143
45–54 years 171 (9.8) 201 (8.9) 171 (9.8) 153 (8.8)
55–64 years 455 (26.1) 618 (27.3) 454 (26.1) 479 (27.5)
65–74 years 628 (36.0) 777 (34.3) 626 (36.0) 603 (34.7)
75–80 years 275 (15.8) 369 (16.3) 274 (15.8) 270 (15.5)
> 80 years 187 (10.7) 273 (12.1) 187 (10.8) 213 (12.2)
BMI category, n (%)
Underweight (< 18.5) 79 (4.5) 78 (3.4) 0.076 79 (4.5) 55 (3.2) 0.235
Normal (18.5–24.9) 512 (29.3) 662 (29.2) 512 (29.4) 509 (29.3)
Overweight (25–29.9) 436 (25.0) 629 (27.8) 434 (25.0) 484 (27.8)
Obese (30–39.9) 361 (20.7) 418 (18.5) 358 (20.6) 325 (18.7)
Severely obese (≥ 40) 26 (1.5) 47 (2.1) 26 (1.5) 39 (2.2)
Missing 331 (19.0) 430 (19.0) 330 (19.0) 327 (18.8)
Smoking status, n (%)
Current 726 (41.6) 994 (43.9) 0.097 725 (41.7) 750 (43.1) 0.513
Non-smoker/never smoked 90 (5.2) 85 (3.8) 88 (5.1) 67 (3.9)
Ex-smoker 773 (44.3) 972 (42.9) 770 (44.3) 761 (43.8)
Missing 156 (8.9) 213 (9.4) 156 (9.0) 161 (9.3)
IMD quintile, n (%)
I 292 (16.7) 322 (14.2) 0.175 291 (16.7) 249 (14.3) 0.254
II 326 (18.7) 411 (18.2) 325 (18.7) 313 (18.0)
III 336 (19.3) 438 (19.3) 334 (19.2) 352 (20.2)
IV 390 (22.3) 526 (23.2) 388 (22.3) 387 (22.3)
V 399 (22.9) 565 (23.2) 399 (22.9) 436 (25.1)
2017 GOLD classification, n (%)
GOLD A 1044 (59.8) 1479 (65.3) < 0.001 1044 (60.0) 1068 (61.4) 0.356
GOLD B 701 (40.2) 785 (34.7) 695 (40.0) 671 (38.6)
Comorbidities, n (%)
Eosinophilia (> 0.4 × 109/L) 119 (6.8) 153 (6.8) 0.933 119 (6.8) 127 (7.3) 0.942
Eosinophilia (> 0.3 × 109/L) 326 (18.7) 399 (17.6) 0.683 326 (18.7) 307 (17.7) 0.822
Eosinophilia (read code) < 5 (−) < 5 (−) 0.214 < 5 (−) < 5 (−) 0.942
Asthma diagnosed > 1 year prior 310 (17.8) 304 (13.4) < 0.001 304 (17.5) 273 (15.7) 0.093
Type II diabetes 271 (15.5) 339 (15.0) 0.627 270 (15.5) 267 (15.4) 0.888
Osteoporosis/osteopenia 227 (13.0) 286 (12.6) 0.724 227 (13.1) 225 (12.9) 0.921
Stroke 118 (6.8) 144 (6.4) 0.610 117 (6.7) 115 (6.6) 0.893
Myocardial infarction 166 (9.5) 238 (10.5) 0.297 166 (9.5) 166 (9.5) 1.000
Pneumonia 357 (20.5) 443 (19.6) 0.484 356 (20.5) 356 (20.5) 1.000
Prior exacerbations 711 (40.7) 895 (39.5) 0.437 709 (40.8) 705 (40.5) 0.890
BMI body–mass index, FEV1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, IMD
Index of Multiple Deprivation - where I is most deprived, SD standard deviation
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Baseline characteristics of the study population pre- and
post-matching are shown in Table 1. In the total matched
cohort, there were more male than female patients (60.5%
versus 39.5%) and the mean age was 67.8 years (SD:
10 years). On average, patients were diagnosed between
2009 and 2013 (mean: 2011; SD: 2 years). Just under half
(47.9%) had a BMI greater than 25 kg/m2, and 42.4% were
current smokers. Similar proportions of patients had
comorbid type 2 diabetes (15.4%), asthma diagnosed more
than one year prior to COPD diagnosis (16.6%) and an
eosinophil count > 0.3 × 109/L (18.2%).
Table 2 shows the total events in the ICS and non-
ICS groups. Fewer short-acting therapy prescriptions
were administered in the non-ICS group (p < 0.05). All
outcomes, with the exception of respiratory-specific
hospital interactions (with a difference of 64 events), were
numerically higher for the ICS-containing group. Al-
though not statistically significant, ‘all HCP interactions’
Table 2 Healthcare resource use during study follow-up
Outcome Total ICS versus non-ICS
Adjusted Unadjusted
ICS Non-ICS Relative rate (95% CI) P value* Relative rate (95% CI) P value*
Short-acting therapy prescriptions 24,063 21,163 1.05 (0.97–1.14) 0.212 1.09 (1.01–1.18) 0.026
All-cause interactions
All HCP 72,802 69,136 1.07 (1.00–1.14) 0.061 1.05 (0.98–1.13) 0.156
GP 55,927 52,947 1.07 (1.00–1.14) 0.063 1.06 (0.98–1.13) 0.129
Outpatient 13,497 12,989 1.01 (0.94–1.08) 0.802 1.04 (0.93–1.16) 0.485
Hospital 3378 3200 1.05 (0.93–1.19) 0.434 1.06 (0.94–1.19) 0.377
Respiratory-related interactions
All HCPa 20,555 19,543 1.04 (0.98–1.12) 0.209 1.05 (0.98–1.13) 0.154
Routine GP 16,391 15,409 1.05 (0.99–1.13) 0.127 1.06 (0.99–1.14) 0.078
Unplanned GP 2166 2085 1.04 (0.92–1.18) 0.506 1.04 (0.92–1.17) 0.530
Outpatient 247 234 1.04 (0.78–1.39) 0.809 1.06 (0.80–1.40) 0.705
Hospital 1751 1815 0.95 (0.83–1.09) 0.465 0.96 (0.84–1.10) 0.603
*Significant at α = 0.05; aGP + outpatient + hospital
CI confidence interval, GP general practitioner, HCP healthcare practitioner, ICS inhaled corticosteroid
Fig. 3 Forest plot of rate ratios for outcomes assessed. HCP, healthcare practitioner; GP, General Practitioner; RR, respiratory-related; RRR, routine
respiratory-related; SABA, short-acting β2 agonist; SAMA, short-acting muscarinic agonist; URR, unplanned respiratory-related
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Fig. 4 Rate ratios for subgroup analyses. a Patients with one previous exacerbation. b Patients with an eosinophil level > 0.3 × 109/L. c Patients
with FEV1 < 50% predicted. HCP, healthcare practitioner; GP, General Practitioner; RR, respiratory-related; RRR, routine respiratory-related; SABA,
short-acting β2 agonist; SAMA, short-acting muscarinic agonist; URR, unplanned respiratory-related
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approached significance, likely driven by the difference in
GP visits between the groups.
The direction of relative rates favoured non-ICS con-
taining therapy in all outcomes, with the exception of
respiratory-specific hospital interactions (Fig. 3).
Subgroup analyses showed similar trends, with ad-
justed outcome relative rates generally favouring the
non-ICS group. Figure 4 demonstrates this for three key
patient subgroups.
Discussion
CPRD, when linked to HES, provides an important re-
pository of data regarding the diagnosis, treatment and
ongoing care of UK patients from the primary to the
secondary care setting. According to analysis of this
data, almost half of GOLD A/B COPD patients were
prescribed an ICS-containing regimen between 2005 and
2015. Despite the widespread use of ICS, no significant
differences in rate of healthcare resource use were iden-
tified in this study.
In pertinent subgroups of GOLD A/B patients in
which escalation to ICS is sometimes advocated in clin-
ical practice, i.e. those who have experienced an exacer-
bation, have poorer lung function or have elevated
eosinophils, the benefit is uncertain. Recent trials of ICS
have enrolled patients with a history of only one exacer-
bation in the prior year (which results in a classification
of GOLD A/B). Recent evidence, including from the
FLAME study, has demonstrated that bronchodilators
can be equally or more effective in preventing exacerba-
tions compared to ICS/LABA [5]. Blood eosinophil
counts have been advocated as a biomarker to predict ICS
response, and influential authors have advocated ICS use
in patients with eosinophil counts > 2% or > 0.3 × 109/L.
There are caveats regarding this analysis, specifically that
most evidence for prediction of ICS response from
eosinophil counts is from post-hoc analyses of prior stud-
ies, and most studies enrolled severe patients with a his-
tory of frequent exacerbations. For patients with poorer
lung function, there is a conflict between the 2010 NICE
guidelines [18], which advocate ICS/LABA use for pa-
tients with FEV1 < 50% predicted, and the GOLD 2017
strategy [2], which promotes ICS use only for patients
with two or more exacerbations (or one hospital admis-
sion) in the previous year.
It should be noted that this study was not designed to
observe the clinical impact of ICS and its potential bene-
fit to some patients; however, the finding that these key
patient subgroups do not seem to experience any benefit
from initial ICS therapy in terms of HCP interactions is
important in view of the current debate on the role of
ICS. The rationale for the addition of ICS in these pa-
tients, which is contrary to GOLD guidelines [2], should
be considered in the context of these findings.
Limitations in read coding meant that conclusions
were more difficult to draw for respiratory-related out-
comes, and results of this analysis should be interpreted
with caution; however, results appear supportive of the
primary findings.
On visual inspection, baseline demographics and
clinical characteristics of the treatment groups are
considered representative of those seen in clinical
practice. In terms of patient numbers, a considerable
proportion of the starting cohort were excluded at
the point of requiring a read code for confirmed spir-
ometry; a record of spirometry confirmed COPD is
considered essential to ensure the analysis cohort rep-
resented true COPD patients (and not those that ac-
tually had asthma or other respiratory condition) [24].
In spite of this, patient numbers were large enough
to statistically power the analysis.
Prior to analysis, the matching process attempted to
correct for potential biases; however, common to all
CPRD analyses, certain biases (e.g. practitioner read
code fluency) cannot be ruled out. It is, however, consid-
ered that the results of this study are largely generalis-
able to the UK.
Conclusions
Despite marketing authorisation, clinical rationale and
guideline support for reserving ICS use in more severe
patients, ICS is commonly prescribed in patients without
exacerbating COPD [2, 3, 8–13, 15–17]. This study dem-
onstrates that there is no reduction in healthcare resource
use, rather results tended toward an increase, when ICS is
prescribed on top of maintenance bronchodilation. This
held for important patient subgroups, e.g. those with
FEV1 < 50% predicted, a history of exacerbations and an
eosinophil count > 0.3 × 109/L. Results suggest that, within
the UK healthcare system, there may be opportunity to
improve patient care and potentially reduce resource use
for patients receiving maintenance treatment for GOLD
A/B COPD.
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